Efficacy Study of a Food Supplement With Myo-inositol, N-Acetyl-Cystein, Zinc and Vitamins on Sperm DNA Fragmentation

Summary

In industrialised countries, it is estimated that about 15% of couples who wish to have a child are currently facing infertility problems, of which, in half of the cases, an anomaly in sperm quality or at least a factor of male origin is identified. The evaluation of sperm quality in males is based, for the most part, on the micro and macroscopic examination of various parameters (concentration, motility, physical abnormalities of the spermatozoa, etc.). Nevertheless, an increasing number of scientific studies have shown that the quality of sperm DNA, and in particular its fragmentation rate, is also associated with a lower fertilisation rate. The integrity of sperm DNA may be affected by an imbalance in the Red/Ox balance leading to uncompensated oxidative stress, and could be restored or improved by dietary hygiene measures and the consumption of specific dietary products. The ISITOL clinical study aims to evaluate the efficacy of a dietary supplement specifically formulated to target the various issues associated with male infertility, and in particular to contribute to the improvement of the sperm DNA fragmentation rate. The efficacy of the dietary supplement Isitol® (GYNOV SAS) on sperm DNA fragmentation rate and other secondary parameters is being evaluated through a single-centre, prospective, randomised, double-blind, interventional vs. placebo clinical study being conducted in France at Laboratoire Drouot (21 Rue Drouot - 75009 Paris - France) and led by Dr. Nino-Guy Cassuto. A total of 72 men aged between 20 and 45 years, with sperm DNA fragmentation rate ≥ 30% and with negative semen culture are recruited. The recruited patients were randomized in a 1:1 scheme into 2 groups (Isitol® treated vs placebo treated).

\[Results to be reported later\]

Conditions

• Male Infertility

Interventions

DIETARY_SUPPLEMENT

Isitol®

1 sachet of Isitol® (2,1g) contains : * 1000 mg of myo-inositol ; * 300 mg of N-acetyl-cystein ; * 48.5 mg of zinc citrate (equivalent zinc pure element : 15 mg) ; * 35 mg of D-a-tocopherol (equivalent vitamin E pure element : 12 mg) ; * 16 mg of vitamin B3 ; * 1.8 mg of pyridoxin hydrochloride (equivalent vitamin B6 pure element : 1.4 mg) ; * 1.4 mg of vitamin B2 ; * 0.37 mg of (6S)-5-methyltetrahydrofolic acid, glucosamine salt (equivalent vitamin B9 pure element : 0.2 mg). Sachets are packaged in box of 30.

OTHER

Placebo

1 sachet of placebo (2,1g) contains : * 1765.1 of maltodextrin ; * 300 mg of magnesium carbonate ; * 40 mg of citric acid ; * 5.3 mg of beta-carotene ; * 2.16 mg of silicon dioxide ; * 1.44 mg of sucralose. Sachets are packaged in box of 30.

Sponsors & Collaborators

• Laboratoire Drouot

  collaborator UNKNOWN

• GYNOV

  lead INDUSTRY

Principal Investigators

• Nino-Guy Cassuto, PharmD · Laboratoire Drouot

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

45 Years

Sex

MALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-07-07

Primary Completion

2026-04-30

Completion

2026-07-31

Countries

• France

Study Locations